Actively Recruiting
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
Led by ENA Respiratory Pty Ltd · Updated on 2026-02-11
1100
Participants Needed
5
Research Sites
61 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurrence, severity, and/or the duration of illness resulting from respiratory virus infections. The trial will enroll generally healthy adults (age 18 - 45 years) who are at risk for exposure to viral respiratory infection, for example, due to living conditions or occupation. Participants will be treated with INNA-051 or placebo once weekly for 4 weeks (Part A) or 12 weeks (Part B) during the respiratory virus season.
CONDITIONS
Official Title
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
Who Can Participate
Eligibility Criteria
You may qualify if you...
- In good general health without significant medical, psychiatric, chronic, or intermittent conditions
- At risk for exposure to viral respiratory infection due to living or working conditions such as crowded housing, childcare, healthcare, factory work, public transportation, or education
- Agree to use highly effective birth control
You will not qualify if you...
- Diagnosed with Type I or Type II diabetes, asthma, or other chronic respiratory conditions
- Have active infections including Hepatitis B, Hepatitis C, or HIV
- Currently participating in another clinical trial involving investigational products or received such products within the past 90 days or five half-lives
- Showing active clinical signs or symptoms of acute respiratory illness such as runny nose, sore throat, or fever
- Received Respiratory Syncytial Virus (RSV) or COVID-19 vaccine within the last 180 days
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
Center for Vaccine Development and Global Health (CVD)
Baltimore, Maryland, United States, 21201
Actively Recruiting
2
Naval Medical Research Command (NMRC)
Bethesda, Maryland, United States, 20889
Actively Recruiting
3
Accellacare of Raleigh
Raleigh, North Carolina, United States, 27609
Actively Recruiting
4
Accellacare of Piedmont HealthCare
Statesville, North Carolina, United States, 28625
Actively Recruiting
5
Accellacare - Wilmington
Wilmington, North Carolina, United States, 20841
Actively Recruiting
Research Team
E
ENA Respiratory
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here